Orexo
In opioid case, NY wants to probe Teva's control of Teva USA
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OREXO AB and OREXO US, INC., Plaintiffs, ACTAVIS ELIZABETH LLC,
In opioid case, NY wants to probe Teva's control of Teva USA
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Orexo sues Actavis and Teva over narcotic dependency treatment
Orexo seeks approval of nasal high-dose opioid rescue medicine
Swedish Pharmaceutical Company: Orexo soars after winning opioid drug appeal against Teva, Health News, ET HealthWorld
Orexo misses out on millions after losing patent infringement suit against Actavis
Opioid Use Disorder Market Growth to register a CAGR of 8.7% to reach USD US$ 4,911.8 Million by 2028 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, | Medgadget
Teva unloads plant, U.S. OTC line to PL Developments | Fierce Pharma
Teva extends global rebrand with tailored marketing messages for caregivers | Fierce Pharma
Teva Can Challenge Validity of Orexo Patent (Corrected)
Orexo Ruling Hugely Significant | Potter Clarkson
Orexo launches digital therapies for depression, alcohol misuse early in US | pharmaphorum
Patent Litigation Updates: CRISPR, Acorda's Ampyra, and Orexo Versus Teva | BioSpace
Teva Seeks to Consolidate Price-Fixing, Opioid Lawsuits
Orexo partners with Gaia on digital opioid abuse therapeutic | Pharmaphorum
Opioid Use Disorder Market Analysis to 2027 - Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, Omeros
Orexo removes overhang on shares with key court win | Evaluate
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OREXO AB and OREXO US, INC., Plaintiffs, ACTA VIS ELIZABETH LLC
Opioid Use Disorder Market Is Booming Worldwide 2023-2030 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. - Digital Journal
Suboxone sales down as opioid addiction drug market intensifies
Teva Can Challenge Validity of Orexo Patent (Corrected)
